½ÃÀ庸°í¼­
»óǰÄÚµå
1660666

Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå º¸°í¼­ : Á¦Ç° À¯Çü, ¿ëµµ, Æ®·£½ºÆå¼Ç ¹æ¹ý, ±â¼ú, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)

Transfection Technologies Market Report by Product Type, Application, Transfection Method, Technology, End-User, and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 147 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå ±Ô¸ð´Â 2024³â 12¾ï 5,890¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 23¾ï 3,870¸¸ ´Þ·¯¿¡ À̸£¸ç, 2025³âºÎÅÍ 2033³â±îÁö 7.1%ÀÇ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

Æ®·£½ºÆå¼Ç ±â¼úÀ̶õ, µ¥¿Á½Ã¸®º¸ ÇÙ»ê(DNA), ¸®º¸ ÇÙ»ê(RNA), ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå µîÀÇ ÇÙ»êÀ» ÀΰøÀûÀ¸·Î ¼¼Æ÷¿¡ µµÀÔÇÏ´Â °úÁ¤À» ¸»ÇÕ´Ï´Ù. ÇÙ»êÀº ´Ù¾çÇÑ ¹°¸®Àû, È­ÇÐÀû, »ý¹°ÇÐÀû ¹æ¹ýÀ» »ç¿ëÇÏ¿© µµÀÔµÇ¾î ¼¼Æ÷ÀÇ Æ¯Á¤ ¼ºÁúÀ» º¯È­½ÃŰ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÄÚÆ®·£½ºÆå¼Ç, ÀÏ·ºÆ®·ÎÆ÷·¹À̼Ç, ¾çÀ̿¼º ÁöÁú Æ®·£½ºÆå¼Ç, »ýü ³» Æ®·£½ºÆå¼Ç µî ´Ù¾çÇÑ ¹æ¹ýÀÌ ÀÖ½À´Ï´Ù. ÀÌ °úÁ¤Àº À¯ÀüÀÚ ¹ßÇö, ½ºÅ©¸®´×, RNA °£¼·, ¹ÙÀÌ·¯½º ¹× ´Ü¹éÁúÀÇ »ý¹°ÇÐÀû »ý»êÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ À¯Àüü ¿¬±¸¿¡ ÀϹÝÀûÀ¸·Î »ç¿ëµË´Ï´Ù.

¾Ï°ú ´Ù¾çÇÑ ¸¸¼º »ýȰ ½À°üº´ÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. °Ô´Ù°¡ ½Ã¾à ±â¹Ý ¹æ¹ýÀÌ ³Î¸® ä¿ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀüÅëÀûÀ¸·Î »ç¿ëµÈ ±â¼ú°ú ºñ±³ÇÒ ¶§, ½Ã¾à ±â¹Ý Æ®·£½ºÆå¼ÇÀº Åõ¿©¿¡ ¾î·Á¿òÀÌ ¾ø°í ºñ¿ë È¿°úÀûÀÔ´Ï´Ù. ÀÌ¿¡ µû¶ó ¹ÙÀÌ¿À¸®½ºÆ½ ±â¼ú, ¸¶ÀÌÅ©·ÎÀÎÁ§¼Ç, ·¹ÀÌÀú Æå¼Ç µîÀÇ ±â±â ±â¹ÝÀÇ ¹æ¹ýµµ ¼¼°è¿¡¼­ Àý´ëÀûÀÎ ÁöÁö¸¦ ¾ò°í ÀÖ½À´Ï´Ù. ¼¼Æ÷ ¿¬±¸¿Í Ä¡·á¹ýÀÇ ¹ß°ß¿¡ À־ÀÇ ´Ù¾çÇÑ ±â¼úÀû Áøº¸µµ ¼ºÀåÀ» °¡¼ÓÇÏ´Â Å« ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²², À¯ÀüÀÚ µµÀÔ ¿¬±¸´Â ½Å±Ô Ä¡·áÁ¦ÀÇ °³¹ß ¹× ±âŸ ´Ù¾çÇÑ ÀÀ¿ëÀ» À§ÇØ ÁÖ·Î »ýü³» Á¶°Ç ÇÏ¿¡¼­ ¼öÇàµË´Ï´Ù. ±âŸ ¿äÀÎÀ¸·Î´Â ´ë±Ô¸ð Æ®·£½ºÆå¼Ç ½Ã¼³ °³¹ßÀ» À§ÇÑ Á¤ºÎ ¹× ¹Î°£ Á¶Á÷ÀÇ ÅõÀÚ Áõ°¡, ´Ü¹éÁú Ä¡·áÁ¦ ºÐ¾ßÀÇ ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿ µîÀÌ ÀÖ¾î ½ÃÀåÀ» ´õ¿í °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • 2024³â ¼¼°èÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå ±Ô¸ð´Â?
  • 2025-2033³â ¼¼°èÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°èÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
  • ¼¼°èÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâÀº?
  • ¼¼°èÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀåÀÇ Á¦Ç° À¯Çüº° ³»¿ªÀº?
  • ¼¼°èÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀåÀÇ ¿ëµµº° ³»¿ªÀº?
  • ¼¼°èÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀåÀÇ Æ®·£½ºÆå¼Ç ¹æ¹ýº° ³»¿ªÀº?
  • ¼¼°èÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀåÀÇ ±â¼úº° ³»¿ªÀº?
  • ¼¼°èÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå¿¡¼­ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°èÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå¿¡¼­ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ Æ®·£½ºÆå¼Ç ±â¼ú ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç° À¯Çüº°

  • ½Ã¾à
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±â±â
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ºÐ¼® : ¿ëµµº°

  • Ä¡·á Àü´Þ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¹ÙÀÌ¿À¸ÞµðÄà ¿¬±¸
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ´Ü¹éÁú »ý»ê
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ºÐ¼® : Æ®·£½ºÆå¼Ç ¹æ¹ýº°

  • ¸®Æ÷Æå¼Ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ÀÏ·ºÆ®·ÎÆ÷·¹À̼Ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ´ºÅ¬·¹¿ÀÆå¼Ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ÄÚÆ®·£½ºÆå¼Ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¾çÀ̿¼º ÁöÁú Æ®·£½ºÆå¼Ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • »ýü ³» Æ®·£½ºÆå¼Ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ºÐ¼® : ±â¼úº°

  • ¹°¸®Àû Æ®·£½ºÆå¼Ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¹ÙÀÌ¿ÀÄɹÌÄ® ±â¹ÝÀÇ Æ®·£½ºÆå¼Ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¹ÙÀÌ·¯½º º¤ÅÍ ±â¹ÝÀÇ Æ®·£½ºÆå¼Ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦10Àå ½ÃÀå ³»¿ª : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¿¬±¸¼¾ÅÍ ¹× Çмú±â°ü
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • º´¿ø ¹× Áø·á¼Ò
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦11Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦12Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦13Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦14Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • °æÀïµµ
  • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Agilent Technologies Inc.
    • Bio-RAD Laboratories Inc.
    • Lonza Group AG
    • Maxcyte Inc.
    • Mirus Bio LLC
    • Polyplus Transfection
    • Promega Corporation
    • Roche Holding AG
    • Sigma-Aldrich Corporation
    • Thermo Fisher Scientific Inc.
KTH 25.03.10

The global transfection technologies market size reached USD 1,258.9 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,338.7 Million by 2033, exhibiting a growth rate (CAGR) of 7.1% during 2025-2033.

Transfection technology refers to the process of artificially introducing nucleic acid, such as Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA) and oligonucleotides, into the cells. It is introduced using various physical, chemical and biological methods, which can assist in modifying certain properties of the cell. It involves various methods, including cotransfection, electroporation, cationic lipid transfection and in-vivo transfection. This process is commonly used for various genomic studies that include gene expression, screening, RNA interference and Vivo research, along with the bioproduction of viruses and proteins.

The increasing prevalence of cancer and various chronic lifestyle diseases is one of the key factors driving the growth of the market. Furthermore, widespread adoption of reagent-based methods is also providing a boost to the market growth. In comparison to the traditionally used techniques, reagent-based transfection is less complicated to administer and more cost-effective. In line with this, instrument-based methods, such as biolistic technology, microinjection and laserfection, are also gaining immense traction across the globe. Various technological advancements in cell research and therapeutic discovery are acting as another major growth-inducing factor. In line with this, research in gene transfer is majorly performed under in-vivo conditions for the development of novel therapeutic drugs and various other applications. Other factors, including increasing investments by both government and private organizations to develop large scale transfection facilities, along with extensive research and development (R&D) activities in the field of protein therapeutics, are projected to drive the market further.

Key Market Segmentation:

Breakup by Product Type:

  • Reagent
  • Instrument
  • Others

Breakup by Application:

  • Therapeutic Delivery
  • Bio-Medical Research
  • Protein Production
  • Others

Breakup by Transfection Method:

  • Lipofection
  • Eletroporation
  • Nucleofection
  • Cotransfection
  • Cationic Lipid Transfection
  • In-Vivo Transfection
  • Others

Breakup by Technology:

  • Physical Transfection
  • Biochemical Based Transfection
  • Viral-Vector Based Transfection

Breakup by End-User:

  • Research Centers and Academic Institutes
  • Hospitals and Clinics
  • Pharmaceutical and Biotechnology Companies
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Bio-RAD Laboratories Inc., Lonza Group AG, Maxcyte Inc., Mirus Bio LLC, Polyplus Transfection, Promega Corporation, Roche Holding AG, Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., etc.

Key Questions Answered in This Report

  • 1.What was the size of the global transfection technologies market in 2024?
  • 2.What is the expected growth rate of the global transfection technologies market during 2025-2033?
  • 3.What are the key factors driving the global transfection technologies market?
  • 4.What has been the impact of COVID-19 on the global transfection technologies market?
  • 5.What is the breakup of the global transfection technologies market based on the product type?
  • 6.What is the breakup of the global transfection technologies market based on the application?
  • 7.What is the breakup of the global transfection technologies market based on the transfection method?
  • 8.What is the breakup of the global transfection technologies market based on the technology?
  • 9.What are the key regions in the global transfection technologies market?
  • 10.Who are the key players/companies in the global transfection technologies market?10. Who are the key players/companies in the global transfection technologies market?"

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Transfection Technologies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Reagent
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Instrument
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Therapeutic Delivery
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Bio-Medical Research
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Protein Production
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Transfection Method

  • 8.1 Lipofection
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Eletroporation
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Nucleofection
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Cotransfection
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Cationic Lipid Transfection
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 In-Vivo Transfection
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by Technology

  • 9.1 Physical Transfection
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Biochemical Based Transfection
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Viral-Vector Based Transfection
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by End-User

  • 10.1 Research Centers and Academic Institutes
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Hospitals and Clinics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Pharmaceutical and Biotechnology Companies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Agilent Technologies Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bio-RAD Laboratories Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Lonza Group AG
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Maxcyte Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 Mirus Bio LLC
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Polyplus Transfection
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Promega Corporation
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Roche Holding AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
    • 15.3.9 Sigma-Aldrich Corporation
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 Thermo Fisher Scientific Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦